SCHEMBL4548762

SCHEMBL4548762

CNC(=O)c1cc(Oc2ccc3c(NC(=O)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)cccc3c2)ccn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.64
RAF1 P04049 13/20 0.63
BRAF P15056 12/20 0.63
KCNH2 Q12809 1/20 0.63
RET P07949 3/20 0.57
PLK4 O00444 2/20 0.57
AURKA O14965 2/20 0.57
MAPK13 O15264 2/20 0.57
MAP4K4 O95819 2/20 0.57
ABL1 P00519 2/20 0.57
LCK P06239 2/20 0.57
FYN P06241 2/20 0.57
LYN P07948 2/20 0.57
SRC P12931 2/20 0.57
RPS6KB1 P23443 2/20 0.57
EPHA2 P29317 2/20 0.57
AXL P30530 2/20 0.57
FRK P42685 2/20 0.57
MAPK9 P45984 2/20 0.57
BLK P51451 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748155 0.94 KDR (0.74) KDRRAF1BRAFKCNH2RET
SCHEMBL2748670 0.94 KDR (0.62) KDRRAF1BRAFKCNH2RET
SCHEMBL2748133 0.88 KDR (0.56) KDRRAF1BRAFKCNH2RET
SCHEMBL2746821 0.87 RAF1 (0.61) KDRRAF1BRAFKCNH2RET
SCHEMBL2747846 0.87 KDR (0.57) KDRRAF1BRAFRETPLK4
SCHEMBL4548770 0.87 KDR (0.58) KDRRAF1BRAFKCNH2RET
SCHEMBL2746237 0.87 KDR (0.60) KDRRAF1BRAFMETFGFR1
SCHEMBL2747211 0.86 KDR (0.58) KDRRAF1BRAFHIPK4MET
SCHEMBL4548758 0.86 KDR (0.59) KDRRAF1BRAFFGFR1FGFR2
SCHEMBL4548728 0.86 KDR (0.70) KDRRAF1BRAFRETPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885RAF1 1183/4885BRAF 170/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885RAF1 1183/4885BRAF 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.